763 results on '"Pinedo, Herbert M"'
Search Results
202. Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts
203. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines
204. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase
205. A Structurally Altered Human Reduced Folate Carrier with Increased Folic Acid Transport Mediates a Novel Mechanism of Antifolate Resistance
206. Clinical resistance to topoisomerase-targeted drugs
207. Construction and Characterization of a Fusion Protein of Single-Chain Anti-CD20 Antibody and Human β-Glucuronidase for Antibody-Directed Enzyme Prodrug Therapy
208. Drug Resistance in the Treatment of Cancer
209. Impaired DNA repair capacity in skin fibroblasts from various hereditary cancer-prone syndromes
210. Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human β-glucuronidase
211. Management of Stage III Breast Cancer
212. [186Re]-labeled mouse and chimeric monoclonal antibody 323/A3: A comparison of the efficacy in experimental human ovarian cancer
213. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma
214. Comparison of the biodistribution and the efficacy of monoclonal antibody labeled with either 131I or 186Re in human ovarian cancer xenografts
215. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression
216. Gemcitabine: Future Prospects of Single-Agent and Combination Studies
217. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
218. Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody in experimental human ovarian cancer
219. Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer
220. CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants
221. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells
222. Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy
223. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung
224. A facile method for the labeling of proteins with zirconium isotopes
225. Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine
226. Drug Resistance
227. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung
228. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity
229. A Monoclonal Antibody against Human β-Glucuronidase for Application in Antibody-Directed Enzyme Prodrug Therapy
230. The drug resistance-related protein LRP is the human major vault protein
231. Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: Potentiating or reversing effect?
232. Production of highly pure no-carrier added 89Zr for the labelling of antibodies with a positron emitter
233. Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells
234. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells
235. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures
236. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression
237. The multidrug‐resistance‐reverser verapamil interferes with cellular P‐glycoprotein‐mediated pumping of daunorubicin as a non‐competing substrate
238. Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study
239. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice
240. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA
241. Effect of folate diastereoisomers on the binding of 5-fluoro-2'-deoxyuridine-5'- monophosphate to thymidylate synthase
242. Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures
243. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89
244. Interleukin‐2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia
245. Malignant Leydig Cell Tumor of the Testis in Complete Remission on o, p′-Dichlorodiphenyl-Dichloroethane
246. The effect of schedule, protein binding and growth factors on the activity of suramin
247. Comparison of 131I‐labelled anti‐episialin 139H2 with cisplatin, cyclophosphamide or external‐beam radiation for anti‐tumor efficacy in human ovarian cancer xenografts
248. Influence of dose and schedule on the therapeutic efficacy of131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model
249. Multicenter Phase II Study of Spiroplatin
250. Index.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.